The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
The role of serotonin receptors in the action of atypical antipsychotic drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Self-citationJones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
The Dopamine Hypothesis of Schizophrenia: A Review*
Meltzer, H. Y., & Stahl, S. M. (1976) · Schizophrenia Bulletin · doi:10.1093/schbul/2.1.19 · Cited by 883
Self-citationDo Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605
Self-citationMonsma, F. J., Shen, Y., Ward, R. P., Hamblin, M. W., & Sibley, D. R. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13616-x · Cited by 597
Choudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Self-citationIchikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Self-citationMechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167346 · Cited by 438
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
Self-citationCloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor
Kohen, R., Metcalf, M. A., Khan, N., Druck, T., Huebner, K., Lachowicz, J. E., Meltzer, H. Y., Sibley, D. R., Roth, B. L., & Hamblin, M. W. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010047.x · Cited by 377
Self-citationRNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity
Niswender, C. M., Copeland, S. C., Herrick-Davis, K., Emeson, R. B., & Sanders-Bush, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9472 · Cited by 363
Kehne, J. H., Baron, B. M., Carr, A. A., Chaney, S. F., Elands, J., Feldman, D. J., Frank, R. A., van Giersbergen, P. L., McCloskey, T. C., Johnson, M. P., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12956-x · Cited by 358
Meltzer, H. Y., Arvanitis, L., Bauer, D., Rein, W., & Meta-Trial Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.975 · Cited by 330
Self-citationDe Deurwaerdère, P., Navailles, S., Berg, K. A., Clarke, W. P., & Spampinato, U. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0112-04.2004 · Cited by 306
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
Self-citationAmisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285
Self-citationKapur, S., & Seeman, P. M. (2000) · PubMed · Cited by 284
Niswender, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00223-2 · Cited by 256
Barker, E. L., Westphal, R. S., Schmidt, D., & Sanders-Bush, E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32625-x · Cited by 254
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
MELTZER, H., & HUANG, M. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248
Self-citationAgonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study
Newman-Tancredi, A., Gavaudan, S., Conte, C., Chaput, C., Touzard, M., Verrièle, L., Audinot, V., & Millan, M. J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00483-x · Cited by 227
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Gray, J. A., & Roth, B. L. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm074 · Cited by 225
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
Bantick, R. A., Deakin, J. F. W., & Grasby, P. M. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500108 · Cited by 214
Roth, B. L., Craigo, S. C., Choudhary, M. S., Uluer, A., Monsma, F. J., Shen, Y., Meltzer, H. Y., & Sibley, D. R. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38596-4 · Cited by 214
Self-citationVanover, K. E., Weiner, D. M., Makhay, M., Veinbergs, I., Gardell, L. R., Lameh, J., Del Tredici, A. L., Piu, F., Schiffer, H. H., Ott, T. R., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097006 · Cited by 204
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.
Roth, B. L., Ciaranello, R. D., & Meltzer, H. Y. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11452-3 · Cited by 197
Self-citationInverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine2C Receptors
Herrick-Davis, K., Grinde, E., & Teitler, M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38891-3 · Cited by 173
Serotonergic regulation of neuronal excitability in the prefrontal cortex
Andrade, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.015 · Cited by 167
Modulation of Serotonin 2C Receptor Editing by Sustained Changes in Serotonergic Neurotransmission
Gurevich, I., Englander, M. T., Adlersberg, M., Siegal, N. B., & Schmauss, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10529.2002 · Cited by 159
Abdul-Monim, Z., Reynolds, G. P., & Neill, J. C. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.01.019 · Cited by 157
The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia
Sumiyoshi, T., Matsui, M., Yamashita, I., Nohara, S., Kurachi, M., Uehara, T., Sumiyoshi, S., Sumiyoshi, C., & Meltzer, H. Y. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01025-8 · Cited by 154
Self-citationSerotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients
Arora, R. C., & Meltzer, H. Y. (1991) · Journal of Neural Transmission · doi:10.1007/bf01244654 · Cited by 154
Self-citationNagai, T., Murai, R., Matsui, K., Kamei, H., Noda, Y., Furukawa, H., & Nabeshima, T. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1240-6 · Cited by 151
Millan, M. J., Brocco, M., Gobert, A., Joly, F., Bervoets, K., Rivet, J., Newman‐Tancredi, A., Audinot, V., & Maurel, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00858.x · Cited by 149
Lurasidone: a new drug in development for schizophrenia
Meyer, J. M., Loebel, A. D., & Schweizer, E. E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286388 · Cited by 141
Liégeois, J.-F., Ichikawa, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02620-3 · Cited by 137
Self-citationDopamine and Serotonin Receptor Binding and Antipsychotic Efficacy
Richtand, N. M., Welge, J. A., Logue, A. D., Keck, P. E., Strakowski, S. M., & McNamara, R. K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301305 · Cited by 136
Assié, M., Ravailhe, V., Faucillon, V., & Newman‐Tancredi, A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087163 · Cited by 127
Yuen, E. Y., Jiang, Q., Chen, P., Feng, J., & Yan, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801713200 · Cited by 125
The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
Newman‐Tancredi, A. (2010) · PubMed · Cited by 124
Rasmussen, H., Erritzøe, D., Andersen, R., Ebdrup, B. H., Aggernæs, B., Oranje, B., Kalbitzer, J., Madsen, J., Pinborg, L. H., Baaré, W. F. C., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.176 · Cited by 124
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
Meltzer, H. Y., Horiguchi, M., & Massey, B. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2137-8 · Cited by 123
Self-citationEffects of the 5-HT7 receptor antagonist SB-258741 in animal models for schizophrenia
Pouzet, B., Didriksen, M., & Arnt, J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00744-4 · Cited by 120
Arnt, J., Bang‐Andersen, B., Grayson, B., Bymaster, F. P., Cohen, M. P., DeLapp, N. W., Giethlen, B., Kreilgaard, M., McKinzie, D. L., Neill, J. C., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000659 · Cited by 108
Bortolozzi, A. A., Masana, M., Díaz-Mataix, L., Cortés, R., Scorza, M. C., Gingrich, J. A., Tóth, M., & Artigas, F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571000009x · Cited by 92
Snigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J. C., & Meltzer, H. Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156349 · Cited by 88
Self-citationMorbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia
Youssef, H. A., & Waddington, J. L. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02754.x · Cited by 88
Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
Barnes, T. R. E., & McPhillips, M. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803003-00009 · Cited by 86
Wagner, M., Quednow, B. B., Westheide, J., Schlaepfer, T. E., Maier, W., & Kühn, K.-U. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300626 · Cited by 80
Carlsson, M. L., Martin, P., Nilsson, M., Sorensen, S. M., Carlsson, A., Waters, N., & Waters, N. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050144 · Cited by 78
Galici, R., Boggs, J. D., Miller, K. L., Bonaventure, P., & Atack, J. R. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f62d8c · Cited by 64
Hagiwara, H., Fujita, Y., Ishima, T., Kunitachi, S., Shirayama, Y., Iyo, M., & Hashimoto, K. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.11.005 · Cited by 64
Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease
Meltzer, H. Y., Kennedy, J., Dai, J., Parsa, M., & Riley, D. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00060-d · Cited by 60
Self-citationMcCreary, A. C., Glennon, J. C., Ashby, C. R., Meltzer, H. Y., Li, Z., Reinders, J. H., Hesselink, M. B., Long, S., Herremans, A. H. J., van Stuivenberg, H. H., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301098 · Cited by 59
Self-citationSemenova, S., Geyer, M. A., Sutcliffe, J. G., Markou, A., & Hedlund, P. B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.011 · Cited by 53
Navailles, S., Deurwaerdère, P. D., & Spampinato, U. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.035 · Cited by 52
Creed, M. C., Oraha, A., & Nóbrega, J. N. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.01.025 · Cited by 50
Rasmussen, H., Ebdrup, B. H., Erritzøe, D., Aggernæs, B., Oranje, B., Kalbitzer, J., Pinborg, L. H., Baaré, W. F. C., Svarer, C., Lublin, H., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1941-5 · Cited by 44
Steward, L. J., Kennedy, M. D., MORRIS, B. J., & Pratt, J. A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.04.020 · Cited by 42
Wadenberg, M.-L. G., Hicks, P. B., Richter, J. T., & Young, K. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00424-1 · Cited by 39
Asenapine induces differential regional effects on serotonin receptor subtypes
Tarazi, F. I., Moran‐Gates, T., Wong, E., Henry, B., & Shahid, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108095704 · Cited by 39
Antagonism at serotonin 5-HT2A receptors modulates functional activity of frontohippocampal circuit
Gozzi, A., Crestan, V., Turrini, G., Clemens, M., & Bifone, A. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1772-4 · Cited by 33
Long-term effects of neuroleptic drugs on the neuroendocrine system.
Hy, M. (1985) · PubMed · Cited by 31
Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801
Scorza, M. C., Castañé, A., Bortolozzi, A. A., & Artigas, F. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.012 · Cited by 31
Slot, L. A. B., Lestienne, F., Barret-Grévoz, C., Newman‐Tancredi, A., & Cussac, D. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.019 · Cited by 31
Evaluation of the clinical efficacy of asenapine in schizophrenia
Minassian, A., & Young, J. W. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.506188 · Cited by 27
Elsworth, J. D., Jentsch, J. D., Morrow, B. A., Redmond, D. E., & Roth, R. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301448 · Cited by 24
Sumiyoshi, T., Higuchi, Y., Matsui, M., Arai, H., Takamiya, C., Meltzer, H. Y., & Kurachi, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.02.017 · Cited by 24
Self-citationPitsikas, N. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.11.010 · Cited by 18
Carro, L., Raviña, E., Domínguez, E., Brea, J. M., Loza, M. I., & Masaguer, C. F. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.041 · Cited by 14
Frankle, W. G., Lombardo, I., Kegeles, L. S., Slifstein, M., Martin, J. H., Huang, Y. H., Hwang, D., Reich, E., Cangiano, C., Gil, R. B., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110388329 · Cited by 8
Cited by
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
Metadata
- Authors
- Meltzer, H., & Massey, B.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 11
- Issue
- 1
- Pages
- 59-67
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W1986484493
- Cited by
- 381
- References
- 77
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.